1. CDK9 inhibitors in acute myeloid leukemia.
- Author
-
Boffo, Silvia, Damato, Angela, Alfano, Luigi, and Giordano, Antonio
- Subjects
- *
ACUTE myeloid leukemia treatment , *GENOMICS , *GENES , *BIOLOGICAL tags , *CLINICAL trials - Abstract
Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF